Trial Profile

A double-blind, placebo controlled, parallel-group, randomised study of safety, tolerability and efficacy of AMAP102 in patients with osteoarthritis.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Nov 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AMAP 102 (Primary)
Indications Musculoskeletal pain; Osteoarthritis
Focus Biomarker; Therapeutic Use
Sponsors AnaMar AB

Most Recent Events

30 Oct 2014 Individual patient data and final subgroup analyses are expected before the end of 2014, according to an AnaMar media release.
30 Oct 2014 Primary endpoint has not been met (Western Ontario and McMaster Universities Osteoarthritis Index [WOMAC] pain subscale for target knee), according to an AnaMar media release.
30 Oct 2014 Top-line results published in an AnaMar media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com